You are Here
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
Medicine

Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia

A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.

Share
Facebook Twitter Pinterest Linkedin

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *